These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35602580)

  • 1. Most Powerful Test Sequences with Early Stopping Options.
    Tarima S; Flournoy N
    Metrika; 2022 May; 85(4):491-513. PubMed ID: 35602580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing Interim Sample Sizes in Group Sequential Designs.
    Tarima S; Flournoy N
    Stud Health Technol Inform; 2021 May; 278():11-16. PubMed ID: 34042870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules.
    Milanzi E; Molenberghs G; Alonso A; Kenward MG; Verbeke G; Tsiatis AA; Davidian M
    J Biom Biostat; 2016 Feb; 7(1):. PubMed ID: 27175309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events.
    Kashiwabara K; Matsuyama Y; Ohashi Y
    Ther Innov Regul Sci; 2014 Jul; 48(4):444-452. PubMed ID: 30235573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential designs in pragmatic trials: feasibility and assessment of utility using data from a number of recent surgical RCTs.
    Parsons NR; Stallard N; Parsons H; Haque A; Underwood M; Mason J; Khan I; Costa ML; Griffin DR; Griffin J; Beard DJ; Cook JA; Davies L; Hudson J; Metcalfe A
    BMC Med Res Methodol; 2022 Oct; 22(1):256. PubMed ID: 36183085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stopping for sequential restricted tests of binomial distributions.
    Dambrosia JM; Greenhouse SW
    Biometrics; 1983 Sep; 39(3):695-710. PubMed ID: 6652203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian sequential design with binary outcome.
    Zhu H; Yu Q; Mercante DE
    Pharm Stat; 2017 May; 16(3):192-200. PubMed ID: 28251815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage designs with small sample sizes.
    Kieser M; Rauch G; Pilz M
    J Biopharm Stat; 2023 Jan; 33(1):53-59. PubMed ID: 35612521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.